Search for a trial

PSMAfore: A phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617
vs. a Change of androgen receptor-directed therapy in the Treatment of Taxane Naïve Men with Progressive Metastatic Castrate Resistant Prostate Cancer

This study has been transitioned to CTIS with ID 2023-507772-50-00 check the CTIS register for the current data. The purpose of this study is to determine whether 177Lu-PSMA-617, given for 6 cycles at a dose of 7.4 Gigabecquerel (GBq) (200…

Promoting independence in bipolar disorder. Does cognitive remediation training of executive functioning lead to an improvement in wellbeing and personal goals of daily functioning?

Goal of the study is to find out if cognitive remediation focused on executive functioning for patients with bipolar disorder improves (1) functioning on personal goals in everyday life? And (2) improves general wellbeing?Hypotheses:Cognitive…

A PHASE III, RANDOMIZED, OPEN-LABEL STUDY OF PRALSETINIB VERSUS STANDARD OF CARE FOR FIRST-LINE TREATMENT OF RET FUSION-POSITIVE, METASTATIC NON-SMALL CELL LUNG CANCER

This study has been transitioned to CTIS with ID 2023-505035-12-00 check the CTIS register for the current data. This study is designed to assess the efficacy of pralsetinib as compared to Investigator*s choice platinum-based chemotherapy regimen…

A pivotal Phase II randomised, multi-centre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in participants with relapsed/refractory diffuse large B-cell lymphoma (R-R DLBCL), who are not eligible for high-dose chemotherapy and autologous stem cell transplantation

This study has been transitioned to CTIS with ID 2023-506270-13-00 check the CTIS register for the current data. The primary objective is to determine superiority of MB CART2019.1 treatment compared to standard-of-care (SoC) therapy with R GemOx (…

Serotonergic modulation of population receptive fields

The primary objective is to determine the effects of serotonergic stimulation, via the administration of psilocybin, on population receptive fields in different modalities and to relate these effect to specific computational aspects of the divisive…

An International Prospective Open-label, Randomized, Phase III Study comparing 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

This study has been transitioned to CTIS with ID 2023-507970-42-00 check the CTIS register for the current data. The purpose of this study is to evaluate the efficacy and safety of 177Lu-PSMA-617 in combination with Standard of Care, versus Standard…

A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE)

This study has been transitioned to CTIS with ID 2024-512745-16-00 check the CTIS register for the current data. Study AG348-C-017 is a Phase 3, double-blind, randomized, placebo-controlled, multicenter study designed to demonstrate the clinical…

Leflunomide and Hydroxychloroquine combination therapy
for primary Sjögren*s Syndrome

This study has been transitioned to CTIS with ID 2024-510904-36-00 check the CTIS register for the current data. To assess clinical efficacy and safety of Leflunomide/Hydroxychloroquine in pSS patients in a phase IIb placebo-controlled randomized…

A phase 3, randomized, placebo-controlled, double-blind study of vimseltinib to assess the efficacy and safety in patients with tenosynovial giant cell tumor (MOTION)

This study has been transitioned to CTIS with ID 2024-513624-42-00 check the CTIS register for the current data. Primary Objective: • To evaluate anti-tumor activity of vimseltinib using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by…

LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC

This study has been transitioned to CTIS with ID 2023-506784-33-00 check the CTIS register for the current data. To compare EFS of participants in the primary analysis population with Stage II-IIIA RET fusion-positive NSCLC treated with…

A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE-T)

This study has been transitioned to CTIS with ID 2024-512747-23-00 check the CTIS register for the current data. Study AG348-C-018 is a Phase 3, double-blind, randomized, placebo-controlled, multicenter study designed to demonstrate the clinical…

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients with Glycogen Storage Disease Type Ia

This study has been transitioned to CTIS with ID 2023-508750-25-00 check the CTIS register for the current data. Primary: To evaluate the efficacy of DTX401 to reduce or eliminate dependence on exogenous glucose replacement therapy needed to…